恩替卡韦导致乙型肝炎肝硬化患者周围神经病变临床特征*

doi:10.3969/j.issn.1672-5069.2016.02.019

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (2): 200-203.doi: 10.3969/j.issn.1672-5069.2016.02.019

恩替卡韦导致乙型肝炎肝硬化患者周围神经病变临床特征^*

李晨, 游绍莉, 吕飒, 郭丽, 王卉妍, 刘婉姝, 朱冰, 万志红, 辛绍杰, 胡瑾华

100853 北京市解放军医学院（李晨,辛绍杰）; 解放军第302医院肝衰竭诊疗与研究中心（李晨,游绍莉,吕飒,刘婉姝,朱冰,万志红,辛绍杰,胡瑾华）; 解放军第61785部队门诊部（郭丽）; 解放军总参谋部第316医院检验科（王卉妍）

收稿日期:2015-07-30 出版日期:2016-03-10 发布日期:2016-03-04
通讯作者: 辛绍杰,E-mail: xsj302@yahoo.com.cn
作者简介:李晨,男,33岁,博士研究生。主要从事肝脏疾病的基础与临床研究
基金资助:
解放军第302医院院管课题（编号：YNKT2014008）

Clinical observation of entecavir-induced peripheral neuropathy in three patients with HBV related liver cirrhosis

Li Chen, You Shaoli, Lyu Sa

Medical School of PLA,302nd Hospital,Beijing 100853

Received:2015-07-30 Online:2016-03-10 Published:2016-03-04

摘要/Abstract

摘要： 目的总结乙型肝炎肝硬化患者服用恩替卡韦过程中出现周围神经病变的临床特征和处理经验。方法自2011年7月至2013年7月解放军第302医院收治3例服用恩替卡韦过程中出现周围神经病变的乙型肝炎肝硬化患者,对其周围神经病变的临床特征进行总结。采用荧光定量PCR法检测HBV DNA,采用化学发光法检测血清HBsAg和HBeAg、甲状腺功能、维生素B12、叶酸,采用间接免疫荧光法检测自身免疫抗体,采用ICP-MASS质谱分析法检测铅、镉等重金属,使用GE公司E9型超声仪检测四肢血管,使用丹麦维迪公司Keypoint型电生理仪检测神经传导速度和肌电图。结果3例患者均为中年男性,在服用恩替卡韦3天~52周出现周围神经病变,主要表现为四肢末端麻木、疼痛,神经传导速度减慢,肌电图检查均正常;3例患者均停用恩替卡韦,更换为阿德福韦酯抗病毒治疗,并给予B族维生素、复合辅酶、前列地尔、丹参等药物治疗和物理治疗,患者不适症状在1周~5周内恢复,神经传导速度在16~61周内恢复,随访期间未出现复发。结论恩替卡韦可以导致乙型肝炎肝硬化患者出现周围神经病变,临床表现各异。一旦发生,应做到及时停用可疑药物、个体化处理,预后较好。

关键词: 肝硬化, 乙型肝炎, 恩替卡韦, 周围神经病变

Abstract: Objective To investigate the clinical characteristics and disposal experiences of entecavir-induced peripheral neuropathy in three patients with HBV related liver cirrhosis. Methods We had a retrospective analysis about peripheral neuropathy caused by using entecavir in three patients with HBV related liver cirrhosis in our hospital from July 2011 to July 2014. The clinical characteristics of peripheral neuropathy were summarized. The clinical index,serum HBV DNA and neuro-electromyography were routinely carried out. Results The three patients were middle-aged men,the symptoms of peripheral neuropathy appeared from 3 days to 52 weeks after entecavir administration. Numbness and pain in distal limbs were main clinical manifestations. Neuro-electromyography showed peripheral nerves were injured. Electromyogram were normal in the three patients. Entecavir were discontinued and adefovir were given in the three patients. Vitamin B,combined coenzyme, alprostadil,salvia miltiorrhiza and physical exercise were also carried out in this three patients. The symptoms of peripheral neuropathy disappeared 1 to 5 weeks after entecavir discontinuation and the function of peripheral nerves recovered 16 to 61 weeks later. During follow-up,the three patients were not showed recurrence. Conclusion Peripheral neuropathy can be caused by using entecavir in patients with HBV related liver cirrhosis. The clinical manifestation in each patient differs a little. When a patient like this is met,the discontinuation of suspected medicine is recommended and an appropriate treatment should be given. Then the patient would have a good prognosis.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Peripheral neuropathy

李晨, 游绍莉, 吕飒, 郭丽, 王卉妍, 刘婉姝, 朱冰, 万志红, 辛绍杰, 胡瑾华. 恩替卡韦导致乙型肝炎肝硬化患者周围神经病变临床特征^*[J]. 实用肝脏病杂志, 2016, 19(2): 200-203.

Li Chen, You Shaoli, Lyu Sa. Clinical observation of entecavir-induced peripheral neuropathy in three patients with HBV related liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 200-203.

参考文献

[1] Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist,2011,4:55-64.
[2] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[3] Head KA. Peripheral neuropathy:pathogenic mechanisms and alternative therapies. Altern Med Rev,2006,11（4）:294-329.
[4] Azhary H,Farooq MU,Bhanushali M,et al. Peripheral neuropathy:differential diagnosis and management. Am Fam Physic,2010,81（7）:887-892.
[5] Fung L,Seto WK,Lai CL,et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol,2014,29（3）:428-434.
[6] Fodale V,Mazzeo A,Praticò C,et al. Fatal exacerbation of peripheral neuropathy during lamivudine therapy:evidence for iatrogenic mitochondrial damage. Anaesthesia,2005,60（8）: 806-810.
[7] Xu H,Wang Z,Zheng L,et al. Lamivudine/telbivudine-associated neuromyopathy:neurogenic damage,mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol,2014,67（11）: 999-1005.
[8] 张晓红,吴元凯,曹红,等. 恩替卡韦治疗乙型肝炎肝硬化并发周围神经病3例. 中华肝脏病杂志,2012,9（20）:707-708.
]9] 李晨,段学章,胡瑾华. 乙型肝炎肝硬化患者应用恩替卡韦分散片致周围神经病变1例. 肝脏,2012,17（2）:148-149.
[10] Yuan K,Guochun W,Huang Z,et al. Entecavir-associated myopathy:a case report and literature review. Muscle Nerve, 2014,49（4）:610-614.
[11] Brinkman K,ter Hofstede HJ,Burger DM,et al. Adverse effects of reverse transcriptase inhibitors:mitochondrial toxicity as common pathway. AIDS,1998,12（14）:1735-1744.
[12] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009,49 （5 Suppl.）:S185-195.
[13] Lange CM,Bojunga J,Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology,2009,50（6）: 2001-2006.
[14] Lewis W,Day BJ,Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective. Nat Rev Drug Discov,2003,2（10）:812-822.
[15] Mazzucco CE, Hamatake RK, Colonno RJ, et al. Entecavir for reatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemoter, 2008, 52（2）: 598-605.
[16] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南. 实用肝脏病杂志,2013,16（3）:210-216.
[17] Lim CY,Kowdley KV. Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother,2007,60（1）: 2-6.
[18] Zuber M,Gause A. Peripheral neuropathy during interferon-alpha therapy in patients with cryoglobulinemia and hepatitis virus infection. J Rheumatol,1997,24（12）:2488-2489.
[19] Fung J,Lai CL,Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs,2008,17（10）:1581-1588.
[20] Yuen MF,Ahn SH,Lee KS,et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir:results from a multicentre study. J Hepatol,2015,62（3）:526-532.

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.

恩替卡韦导致乙型肝炎肝硬化患者周围神经病变临床特征^*

Clinical observation of entecavir-induced peripheral neuropathy in three patients with HBV related liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价